Zamerovimab (CTB011; SYN023), a composite of human monoclonal antibodies CTB011 and CTB012, targets distinct, non-overlapping epitopes on the rabies virus (RABV) glycoprotein, with CTB011 specifically binding to antigenic site III. This compound is applicable in rabies research [1].

Zamerovimab (CTB011; SYN023) at concentrations ranging from 0.001 to 100 μg/mL for 4 hours induces dose-dependent cytotoxicity in BSR cells infected with CVS, facilitating viral clearance. This cytotoxic effect is also shown to correlate with the cell specificity for expressing the G protein, which are targeted by CTB011 [1].

Zamerovimab (CTB011; SYN023), administered via intramuscular injection into the right gastrocnemius at doses ranging from 0.03 to 1.0 mg/kg for a single dose on day 35, was shown to increase the survival rate of Syrian hamsters infected with the rabies virus RABV BD06 in a dose-dependent manner. At doses of 0.03, 0.1, 0.3, and 1.0 mg/kg, the survival rates were 58%, 83%, 100%, and 100%, respectively [1].